CA2266070A1
(en)
*
|
1996-09-19 |
1998-03-26 |
American Home Products Corporation |
Method of treating urinary incontinence
|
US20100137358A1
(en)
*
|
1996-11-05 |
2010-06-03 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
IL141235A
(en)
*
|
2000-02-09 |
2012-04-30 |
Novartis Int Pharm Ltd |
Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
|
US7858119B1
(en)
*
|
2000-05-09 |
2010-12-28 |
Amina Odidi |
Extended release pharmaceuticals
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
DE10149674A1
(de)
*
|
2001-10-09 |
2003-04-24 |
Apogepha Arzneimittel Gmbh |
Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
|
US7163696B2
(en)
*
|
2001-10-11 |
2007-01-16 |
Pfizer Inc. |
Pharmaceutical formulations
|
US20030185882A1
(en)
*
|
2001-11-06 |
2003-10-02 |
Vergez Juan A. |
Pharmaceutical compositions containing oxybutynin
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
GB0129962D0
(en)
*
|
2001-12-14 |
2002-02-06 |
Pfizer Ltd |
Method of treatment
|
GB0207104D0
(en)
*
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
KR20090118994A
(ko)
|
2002-12-13 |
2009-11-18 |
워너-램버트 캄파니 엘엘씨 |
하부요로증상을 치료하기 위한 알파-2-델타 리간드
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
US20040235857A1
(en)
*
|
2003-02-11 |
2004-11-25 |
Pfizer Inc |
Crystalline therapeutic agent
|
PA8597401A1
(es)
*
|
2003-03-14 |
2005-05-24 |
Pfizer |
Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
|
US20040186046A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
WO2004096810A1
(en)
|
2003-04-29 |
2004-11-11 |
Pfizer Limited |
5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
|
US7268147B2
(en)
*
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
US20050043300A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Pfizer Inc. |
Piperazine derivatives
|
WO2005021539A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Pfizer Japan, Inc. |
Benzimidazolone compounds having 5-ht4 receptor agonistic activity
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
BRPI0414862A
(pt)
*
|
2003-10-03 |
2006-11-28 |
Pfizer |
derivados de tropano substituìdos com imidazopiridina com atividade antagonista do receptor ccr5, para o tratamento do hiv e da inflamação
|
GB0327323D0
(en)
*
|
2003-11-24 |
2003-12-31 |
Pfizer Ltd |
Novel pharmaceuticals
|
US7572799B2
(en)
*
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
GB0402491D0
(en)
*
|
2004-02-04 |
2004-03-10 |
Pfizer Ltd |
Medicaments
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
US7629358B2
(en)
*
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
EP1735284A1
(en)
*
|
2004-03-18 |
2006-12-27 |
Pfizer Limited |
N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
|
US7538141B2
(en)
*
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
US20050215542A1
(en)
*
|
2004-03-23 |
2005-09-29 |
Pfizer Inc |
Compounds for the treatment of diseases
|
AP2315A
(en)
*
|
2004-03-23 |
2011-11-04 |
Pfizer |
Formamide derivatives useful as adrenoceptor.
|
DE602005011784D1
(de)
*
|
2004-04-07 |
2009-01-29 |
Pfizer |
Pyrazoloä4,3-düpyrimidine
|
EA200801608A1
(ru)
*
|
2004-06-15 |
2008-10-30 |
Пфайзер Инк. |
Производные бензимидазолонкарбоновой кислоты
|
US7737163B2
(en)
*
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
JP4084836B2
(ja)
|
2004-08-12 |
2008-04-30 |
ファイザー・インク |
p38MAPキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
PT1784396E
(pt)
*
|
2004-08-26 |
2011-01-27 |
Pfizer |
Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
|
WO2006021884A2
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
ATE417830T1
(de)
*
|
2004-11-02 |
2009-01-15 |
Pfizer |
Sulfonylbenzimidazolderivate
|
US20060111416A1
(en)
*
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
AP2007004157A0
(en)
|
2005-03-17 |
2007-10-31 |
Pfizer |
N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
|
US20110152326A1
(en)
*
|
2005-03-28 |
2011-06-23 |
Takeshi Hanazawa |
Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
MX2007015114A
(es)
*
|
2005-06-15 |
2008-02-15 |
Pfizer Ltd |
Arilpirazoles sustituidos.
|
US7645786B2
(en)
*
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20070149464A1
(en)
*
|
2005-06-15 |
2007-06-28 |
Pfizer Inc. |
Combination
|
JP2009503050A
(ja)
*
|
2005-08-04 |
2009-01-29 |
ファイザー・リミテッド |
ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
|
JP2009504628A
(ja)
*
|
2005-08-10 |
2009-02-05 |
ファイザー・リミテッド |
オキシトシン拮抗薬としての置換トリアゾール誘導体
|
JP5312027B2
(ja)
|
2005-09-02 |
2013-10-09 |
セラヴィダ、インク |
病気の治療法
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
WO2007109142A2
(en)
*
|
2006-03-17 |
2007-09-27 |
Oregon Health & Science University |
M3 muscarinic receptor antagonists for treating tumors
|
EP2007360B1
(en)
|
2006-04-03 |
2014-11-26 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
RS20080525A
(en)
|
2006-05-09 |
2009-09-08 |
Pfizer Products Inc., |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
CA2660261A1
(en)
*
|
2006-08-09 |
2008-02-14 |
Pfizer Products Inc. |
Heterocycles useful as inhibitors of carbonic anhydrase
|
WO2008031221A1
(en)
*
|
2006-09-12 |
2008-03-20 |
Cephalin Pharmaceuticals Inc. |
Isovaline for treatment of pain
|
BRPI0717102A2
(pt)
*
|
2006-09-21 |
2013-10-29 |
Raqualia Pharma Inc |
Derivados de benzimidazol como inibidores seletivos de bomba de ácido
|
WO2008050199A2
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Japan Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
BRPI0808634A2
(pt)
|
2007-02-02 |
2014-08-05 |
Pfizer Prod Inc |
Compostos tricíclicos, composições e métodos.
|
US20100216823A1
(en)
*
|
2007-05-24 |
2010-08-26 |
Pfizer Inc. |
Spirocyclic Derivatives
|
CN101084891A
(zh)
*
|
2007-06-29 |
2007-12-12 |
北京本草天源药物研究院 |
一种用于口服的达非那新或其药用盐的药物制剂
|
WO2009006413A1
(en)
*
|
2007-06-30 |
2009-01-08 |
Auspex Pharmaceuticals, Inc. |
Substituted pyrrolidines
|
US8323695B2
(en)
|
2007-08-13 |
2012-12-04 |
Mcneil-Ppc, Inc. |
Method for stabilizing phenylephrine
|
CZ300895B6
(cs)
*
|
2008-01-28 |
2009-09-02 |
Zentiva, A. S. |
Zpusob prípravy Darifenacinu
|
US20110092564A1
(en)
*
|
2008-02-26 |
2011-04-21 |
Ernest Puil |
Cyclic amino acids for the treatment of pain
|
WO2009140078A1
(en)
*
|
2008-05-16 |
2009-11-19 |
The Procter & Gamble Company |
Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
|
EP2286810A4
(en)
*
|
2008-05-16 |
2011-07-20 |
Axis Inc |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FIBROMYALGIA
|
DK2285357T3
(da)
*
|
2008-05-30 |
2014-06-02 |
Ucb Pharma Sa |
Farmaceutisk sammensætning omfattende brivaracetam
|
ES2378513T3
(es)
*
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
CA2741511C
(en)
|
2008-11-21 |
2017-01-24 |
Raqualia Pharma Inc. |
Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
|
GEP20135992B
(en)
|
2009-01-12 |
2013-12-25 |
Icagen Inc |
Sulfonamide derivatives
|
EP2406281B1
(en)
|
2009-03-12 |
2016-02-17 |
Haase Investments UG |
Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
EP2236516A1
(en)
|
2009-03-31 |
2010-10-06 |
Charité-Universitätsmedizin Berlin (Charité) |
Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury
|
WO2010136940A1
(en)
|
2009-05-29 |
2010-12-02 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
US8617763B2
(en)
*
|
2009-08-12 |
2013-12-31 |
Bloom Energy Corporation |
Internal reforming anode for solid oxide fuel cells
|
EP2509978A1
(en)
|
2009-12-11 |
2012-10-17 |
E.I. Du Pont De Nemours And Company |
Azocyclic inhibitors of fatty acid amide hydrolase
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
CA2786950C
(en)
|
2009-12-23 |
2019-01-15 |
Takeda Pharmaceutical Company Limited |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
GB2479213B
(en)
|
2010-04-01 |
2013-07-10 |
Theravida Inc |
Pharmaceutical formulations for the treatment of overactive bladder
|
EP2566858A2
(en)
|
2010-05-04 |
2013-03-13 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
WO2011161504A1
(en)
|
2010-06-23 |
2011-12-29 |
Micro Labs Limited |
Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
|
JP5830534B2
(ja)
|
2010-07-09 |
2015-12-09 |
ファイザー・リミテッドPfizer Limited |
化合物
|
CA2803118C
(en)
|
2010-07-09 |
2015-11-03 |
Pfizer Limited |
Sulfonamide derivatives as nav 1.7 inhibitors
|
EP2590972B1
(en)
|
2010-07-09 |
2015-01-21 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
EP2593428B1
(en)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
WO2012007877A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
CA2801032A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
EP2593427B1
(en)
|
2010-07-12 |
2014-12-24 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
ES2526981T3
(es)
|
2010-07-12 |
2015-01-19 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
WO2012066442A1
(en)
|
2010-11-15 |
2012-05-24 |
Pfizer Limited |
Inhibitors of hiv replication
|
EP2457900A1
(en)
|
2010-11-25 |
2012-05-30 |
Almirall, S.A. |
New pyrazole derivatives having CRTh2 antagonistic behaviour
|
EP2463289A1
(en)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
CN102048706B
(zh)
*
|
2011-01-12 |
2012-02-22 |
山东创新药物研发有限公司 |
一种氢溴酸达非那新缓释片及制备方法
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
EP2489663A1
(en)
|
2011-02-16 |
2012-08-22 |
Almirall, S.A. |
Compounds as syk kinase inhibitors
|
TW201242971A
(en)
|
2011-02-25 |
2012-11-01 |
Takeda Pharmaceutical |
N-substituted oxazinopteridines and oxazinopteridinones
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
KR20130133905A
(ko)
|
2011-04-05 |
2013-12-09 |
화이자 리미티드 |
트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체
|
EP2518070A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as PI3K inhibitors
|
EP2518071A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Imidazopyridine derivatives as PI3K inhibitors
|
US20120289562A1
(en)
|
2011-05-10 |
2012-11-15 |
Theravida, Inc. |
Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
|
CN103813792B
(zh)
|
2011-05-10 |
2015-11-25 |
塞拉维达公司 |
用于治疗膀胱过度活动症的索利那新和唾液刺激剂的组合
|
CN103702995B
(zh)
|
2011-05-18 |
2016-04-13 |
拉夸里亚创药株式会社 |
4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
|
EP2527344A1
(en)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
|
EP2526945A1
(en)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
New CRTH2 Antagonists
|
JP6026525B2
(ja)
|
2011-06-22 |
2016-11-16 |
武田薬品工業株式会社 |
置換6−アザ−イソインドリン−1−オン誘導体
|
EP2548876A1
(en)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
New CRTh2 antagonists
|
EP2548863A1
(en)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
New CRTh2 antagonists.
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
EP2554544A1
(en)
|
2011-08-01 |
2013-02-06 |
Almirall, S.A. |
Pyridin-2(1h)-one derivatives as jak inhibitors
|
US20160206608A1
(en)
|
2011-08-02 |
2016-07-21 |
Pfizer Inc. |
Crizotinib for use in the treatment of cancer
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
AU2012324491A1
(en)
|
2011-10-19 |
2014-04-17 |
Zoetis Services Llc |
Use of aminoacetonitrile derivatives against endoparasites
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
WO2013061205A2
(en)
|
2011-10-26 |
2013-05-02 |
Pfizer Limited |
Chemical compounds
|
US9273011B2
(en)
|
2011-10-28 |
2016-03-01 |
Inhibitaxin Limited |
Substituted pyridazines for the treatment of pain
|
CA2857603C
(en)
|
2011-12-15 |
2016-08-02 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
CN102600096B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种达非那新缓释制剂及其制备方法
|
CN102579379B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种药物缓释制剂及其制备方法
|
CA2860553C
(en)
|
2012-01-04 |
2016-08-23 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
CA2861439C
(en)
|
2012-02-03 |
2016-07-12 |
Pfizer Inc. |
Benzimidazole and imidazopyridine derivatives as sodium channel modulators
|
AP2014007881A0
(en)
|
2012-03-06 |
2014-08-31 |
Pfizer |
Macrocyclic derivatives for the treatment of proliferative diseases
|
WO2013148603A1
(en)
|
2012-03-27 |
2013-10-03 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives as as btk inhibitors
|
CN104203242B
(zh)
|
2012-04-04 |
2017-03-15 |
杭州德润玉成生物科技有限公司 |
取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
|
TW201414734A
(zh)
|
2012-07-10 |
2014-04-16 |
Takeda Pharmaceutical |
氮雜吲哚衍生物
|
EP2909212B1
(en)
|
2012-09-07 |
2017-02-22 |
Takeda Pharmaceutical Company Limited |
Substituted 1,4-dihydropyrazolo[4,3-b]indoles
|
CA2884921A1
(en)
|
2012-09-18 |
2014-03-27 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
JP6254169B2
(ja)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
JP2015531393A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
トロポミオシン関連キナーゼ阻害剤
|
WO2014053967A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
WO2014053968A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
WO2014060431A1
(en)
|
2012-10-16 |
2014-04-24 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as pi3k inhibitors
|
JP5857168B2
(ja)
|
2012-11-08 |
2016-02-10 |
ファイザー・インク |
ドーパミンd1リガンドとしての複素芳香族化合物およびその使用
|
PE20150966A1
(es)
|
2012-11-08 |
2015-06-21 |
Pfizer |
Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
|
EP2922849B1
(en)
|
2012-11-21 |
2017-07-12 |
RaQualia Pharma Inc. |
Polymorphs of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid as 5-hydroxytryptamine-4 (5-ht4) receptor agonists for the treatment of gastrointestinal diseases
|
EA026562B1
(ru)
|
2012-12-03 |
2017-04-28 |
Пфайзер Инк. |
Новые селективные модуляторы андрогенных рецепторов
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
AR094797A1
(es)
|
2013-02-15 |
2015-08-26 |
Almirall Sa |
Derivados de pirrolotriazina como inhibidores de pi3k
|
PL2958916T3
(pl)
|
2013-02-21 |
2019-01-31 |
Pfizer Inc. |
Stałe postacie selektywnego inhibitora CDK4/6
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
JP2016510787A
(ja)
*
|
2013-03-13 |
2016-04-11 |
ラシオファルム ゲーエムベーハー |
クリゾチニブを含む剤形
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
WO2014186742A2
(en)
|
2013-05-17 |
2014-11-20 |
Acupac Packaging, Inc. |
Anhydrous hydrogel composition
|
CA2916653C
(en)
|
2013-06-27 |
2017-07-18 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
JP2016540811A
(ja)
|
2013-12-20 |
2016-12-28 |
ファイザー・リミテッドPfizer Limited |
N−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
|
WO2015092614A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Inc. |
Activating notch alterations in breast cancer
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
TW201620904A
(zh)
|
2014-01-09 |
2016-06-16 |
武田藥品工業有限公司 |
氮雜吲哚衍生物
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
MD20160112A2
(ro)
|
2014-04-25 |
2017-06-30 |
Pfizer Inc. |
Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
CR20160494A
(es)
|
2014-04-25 |
2016-12-20 |
Pfizer |
Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
|
EP3137469B1
(en)
|
2014-04-28 |
2019-10-09 |
Pfizer Inc |
Heterocyclic compounds and their use as dopamine d1 ligands
|
US9856263B2
(en)
|
2014-04-28 |
2018-01-02 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
AP2016009562A0
(en)
|
2014-05-14 |
2016-11-30 |
Pfizer |
Pyrazolopyridines and pyrazolopyrimidines
|
PT3143019T
(pt)
|
2014-05-15 |
2021-01-28 |
Pfizer |
Forma cristalina de 6-[(4r)-4-metil-1,2-dióxido-1,2,6- tiadiazinan-2-il]isoquinolina-1-carbonitrilo
|
TWI672300B
(zh)
|
2014-05-20 |
2019-09-21 |
日商拉夸里亞創藥股份有限公司 |
苯并異唑衍生物鹽類
|
WO2015181797A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
ES2664810T3
(es)
|
2014-06-12 |
2018-04-23 |
Pfizer Limited |
Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
EA031892B1
(ru)
|
2014-06-17 |
2019-03-29 |
Пфайзер Инк. |
Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
WO2016044433A2
(en)
|
2014-09-16 |
2016-03-24 |
Biopharma Works |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
UY39011A
(es)
|
2015-01-22 |
2021-02-26 |
Phytoplant Res S L |
Métodos para purificar cannabinoides, composiciones y kits de estos
|
CN107278205A
(zh)
|
2015-02-24 |
2017-10-20 |
辉瑞大药厂 |
用作抗癌药的取代的核苷衍生物
|
EP3268046A4
(en)
|
2015-03-13 |
2018-11-21 |
Endocyte, Inc. |
Conjugates for treating diseases
|
EP3286178A1
(en)
|
2015-04-21 |
2018-02-28 |
Almirall S.A. |
Amino-substituted heterocyclic derivatives as sodium channel inhibitors
|
HUE047477T2
(hu)
|
2015-06-04 |
2020-04-28 |
Pfizer |
Palbociclib szilárd dózisformái
|
ES2823049T3
(es)
|
2015-07-31 |
2021-05-05 |
Pfizer |
Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
|
WO2017060488A1
(en)
|
2015-10-09 |
2017-04-13 |
Almirall, S.A. |
New trpa1 antagonists
|
WO2017064068A1
(en)
|
2015-10-14 |
2017-04-20 |
Almirall, S.A. |
New trpa1 antagonists
|
WO2017098367A1
(en)
|
2015-12-10 |
2017-06-15 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
TN2018000221A1
(en)
|
2015-12-24 |
2019-10-04 |
Takeda Pharmaceuticals Co |
Cocrystal, production method thereof, and medicament containing cocrystal
|
EP3399968B8
(en)
|
2016-01-07 |
2021-12-01 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
EP3402796B1
(en)
|
2016-01-15 |
2020-11-18 |
Pfizer Inc |
6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
|
EP3405191A4
(en)
|
2016-01-20 |
2019-09-04 |
TheraVida, Inc. |
METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS
|
US11753626B2
(en)
|
2016-03-09 |
2023-09-12 |
Beijing Percans Oncology Co., Ltd. |
Tumor cell suspension cultures and related methods
|
JP7305352B2
(ja)
|
2016-03-31 |
2023-07-10 |
武田薬品工業株式会社 |
イソキノリニルトリアゾロン錯体
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
CN109789144B
(zh)
|
2016-08-12 |
2022-04-15 |
马德拉医疗公司 |
蛋白激酶调节剂
|
JP6563623B1
(ja)
|
2016-08-15 |
2019-08-21 |
ファイザー・インク |
ピリドピリミジノンcdk2/4/6阻害剤
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
EP3558950B1
(en)
|
2016-12-20 |
2023-05-10 |
Oligomerix, Inc. |
Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
|
SG11201906417RA
(en)
|
2017-01-20 |
2019-08-27 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
SG11201906427QA
(en)
|
2017-01-23 |
2019-08-27 |
Pfizer |
Heterocyclic spiro compounds as magl inhibitors
|
EP3573995A1
(en)
|
2017-01-24 |
2019-12-04 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
DK3600312T3
(da)
|
2017-03-26 |
2023-07-31 |
Takeda Pharmaceuticals Co |
Piperidinyl- og piperazinylsubstituerede heteroaromatiske carboxamider som modulatorer af gpr6
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
EP3642198B1
(en)
|
2017-06-22 |
2022-03-16 |
Curadev Pharma Limited |
Small molecule modulators of human sting
|
CA3073919A1
(en)
|
2017-08-30 |
2019-03-07 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Cyclic di-nucleotides as stimulator of interferon genes modulators
|
US10435389B2
(en)
|
2017-09-11 |
2019-10-08 |
Krouzon Pharmaccuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
SG11202003477QA
(en)
|
2017-11-14 |
2020-05-28 |
Pfizer |
Ezh2 inhibitor combination therapies
|
CA3089490A1
(en)
|
2018-01-29 |
2019-08-01 |
Phytoplant Research S.L |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびbet−ブロモドメイン阻害剤の組合せ
|
AR114421A1
(es)
|
2018-03-01 |
2020-09-02 |
Takeda Pharmaceuticals Co |
Piperidinil-3-(ariloxi)-propanamidas y propanoatos
|
MX2020011294A
(es)
|
2018-04-26 |
2020-11-18 |
Pfizer |
Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina.
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
US20210309669A1
(en)
|
2018-07-19 |
2021-10-07 |
Pfizer Inc. |
Heterocyclic Spiro Compounds As MAGL Inhibitors
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
MX2021008866A
(es)
|
2019-01-23 |
2021-08-19 |
Pfizer |
Forma de polimorfo de sal de hidrato de monofosfato de un derivado conocido de tetra hidroisoquinolina.
|
BR112021012635A2
(pt)
|
2019-01-31 |
2021-12-14 |
Pfizer |
Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
CA3131740A1
(en)
|
2019-02-27 |
2020-09-03 |
Madera Therapeutics, LLC |
Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
|
AR118471A1
(es)
|
2019-03-22 |
2021-10-06 |
Takeda Pharmaceuticals Co |
Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
|
GB201905371D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
GB201905375D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
US20220119361A1
(en)
|
2019-04-29 |
2022-04-21 |
Solent Therapeutics, Llc |
3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
EP4003961A2
(en)
|
2019-07-25 |
2022-06-01 |
Curadev Pharma Pvt. Ltd. |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
GB201912674D0
(en)
|
2019-09-04 |
2019-10-16 |
Mission Therapeutics Ltd |
Novel compounds
|
JP2022548602A
(ja)
|
2019-09-16 |
2022-11-21 |
武田薬品工業株式会社 |
アゾール縮合ピリダジン-3(2h)-オン誘導体
|
CA3166358A1
(en)
|
2020-02-12 |
2021-08-19 |
Monali BANERJEE |
Small molecule sting antagonists
|
WO2021176349A1
(en)
|
2020-03-05 |
2021-09-10 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
JP2023520727A
(ja)
|
2020-04-08 |
2023-05-18 |
ミッション セラピューティクス リミティド |
Usp30阻害剤として活性を有するn-シアノピロリジン
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
CN115698004A
(zh)
|
2020-05-01 |
2023-02-03 |
辉瑞公司 |
作为hpk1抑制剂的氮杂内酰胺化合物
|
IL297456A
(en)
|
2020-05-04 |
2022-12-01 |
Takeda Pharmaceuticals Co |
n-(piperidin-4-yl)benzamide derivatives are active in Nahor
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
EP4157834A1
(en)
|
2020-05-28 |
2023-04-05 |
Mission Therapeutics Limited |
N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
|
CN115698001A
(zh)
|
2020-06-04 |
2023-02-03 |
特殊治疗有限公司 |
具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物
|
WO2021249909A1
(en)
|
2020-06-08 |
2021-12-16 |
Mission Therapeutics Limited |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
WO2022013692A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022018596A1
(en)
|
2020-07-20 |
2022-01-27 |
Pfizer Inc. |
Combination therapy
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
KR20230057384A
(ko)
|
2020-08-13 |
2023-04-28 |
화이자 인코포레이티드 |
조합 요법
|
MX2023003054A
(es)
|
2020-09-15 |
2023-04-05 |
Pfizer |
Formas solidas de un inhibidor de cdk4.
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
GB202016800D0
(en)
|
2020-10-22 |
2020-12-09 |
Mission Therapeutics Ltd |
Novel compounds
|
AU2021405409A1
(en)
|
2020-12-22 |
2023-07-06 |
Effector Therapeutics, Inc. |
Solid forms of an eif4e inhibitor
|
EP4267563A1
(en)
|
2020-12-24 |
2023-11-01 |
Pfizer Inc. |
Solid forms of a cdk2 inhibitor
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
BR112023018906A2
(pt)
|
2021-03-24 |
2023-10-10 |
Astellas Pharma Inc |
Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
WO2022207673A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
EP4320121A2
(en)
|
2021-04-07 |
2024-02-14 |
LifeArc |
2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
|
WO2022229846A1
(en)
|
2021-04-29 |
2022-11-03 |
Pfizer Inc. |
Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
|
WO2022269531A1
(en)
|
2021-06-26 |
2022-12-29 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
WO2023002362A1
(en)
|
2021-07-22 |
2023-01-26 |
Pfizer Inc. |
Treatment of hematological malignancy
|
CA3228653A1
(en)
|
2021-08-11 |
2023-02-16 |
Monali BANERJEE |
Small molecule urea derivatives as sting antagonists
|
KR20240046742A
(ko)
|
2021-08-11 |
2024-04-09 |
큐라데브 파마 프라이버트 리미티드 |
소분자 sting 길항제
|
WO2023084459A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating sars-cov-2
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
WO2023099561A1
(en)
|
2021-12-01 |
2023-06-08 |
Mission Therapeutics Limited |
Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
|
WO2023100134A1
(en)
|
2021-12-02 |
2023-06-08 |
Pfizer Inc. |
Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
TW202345838A
(zh)
|
2022-04-07 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
稠合噠嗪衍生物
|
WO2024013567A1
(en)
|
2022-07-15 |
2024-01-18 |
Jazz Pharmaceuticals Ireland Limited |
Biaryl ether urea compounds as faah inhibitors
|
WO2024023727A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024033513A1
(en)
|
2022-08-11 |
2024-02-15 |
Diaccurate |
Compounds for treating cancer
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|